Prostate Cell News Volume 9.48 | Dec 14 2018

TOP STORY

The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging Let-7

In most patients with prostate cancer (PCa), TTTY15 was the most elevated long noncoding RNA (lncRNA) located on the Y chromosome. Knockout of this lncRNA by two different CRISPR-Cas9 strategies suppressed PCa cell growth both in vitro and in vivo. TTTY15 promoted PCa by sponging the microRNA let-7, consequently increasing CDK6 and FN1 expression. [Eur Urol] Full Article

(Ranked by impact factor of the journal)

KLF4, a Gene Regulating Prostate Stem Cell Homeostasis, Is a Barrier to Malignant Progression and Predictor of Good Prognosis in Prostate Cancer

Scientists propose that genes that control adult stem cell homeostasis in organs with slow turnover, such as the prostate, control cancer fate. One such gene, KLF4, overexpressed in murine prostate stem cells, regulated their homeostasis, blocked malignant transformation, and controlled the self-renewal of tumor-initiating cells. [Cell Rep] Full Article | Graphical Abstract

Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function

Researchers showed that the rs61752561 single-nucleotide polymorphism affected prostate-specific antigen (PSA) stability and structural conformation and created an extra glycosylation site. This PSA variant had reduced enzymatic activity and the ability to stimulate proliferation and migration of prostate cancer cells. [Clin Chem] Abstract

A New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity

The novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders. II and III maintained potency against enzalutamide-resistant (Enz-R) mutant androgen receptors and prostate cancer (PC) cells, and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. [J Med Chem] Abstract

FAM46B Inhibits Cell Proliferation and Cell Cycle Progression in Prostate Cancer through Ubiquitination of β-Catenin

FAM46B silencing promoted cell proliferation and cell cycle progression in prostate cancer (PC), which were abrogated by XAV-939. Moreover, FAM46B overexpression inhibited PC cell cycle progression and cell proliferation in vitro and tumor growth in vivo. [Exp Mol Med] Full Article

AMD3100 Inhibits Epithelial-Mesenchymal Transition, Cell Invasion, and Metastasis in the Liver and the Lung through Blocking the SDF-1α/CXCR4 Signaling Pathway in Prostate Cancer

Human prostate cancer cell lines were cultured to detect stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4), which showed higher SDF-1α and CXCR4 expression than the normal human prostate epithelial cell line, RWPE-1. [J Cell Physiol] Abstract

MicroRNA-16-5p Enhances Radiosensitivity through Modulating Cyclin D1/E1-pRb-E2F1 Pathway in Prostate Cancer Cells

Overexpression of miR-16-5p suppressed cell proliferation, reduced cell viability, and induced cell cycle arrest at G0/G1 phase, resulting in enhanced radiosensitivity in LNCaP cells. Additionally, miR-16-5p specifically targeted the cyclin D1/E1–3′-UTR in LNCaP cells and affected the expression of cyclin D1/E1 in both mRNA and protein levels. [J Cell Physiol] Abstract

Centromere Protein F (CENPF), a Microtubule Binding Protein, Modulates Cancer Metabolism by Regulating Pyruvate Kinase M2 Phosphorylation Signaling

Investigators demonstrated that CENPF, a protein associated with the centromere-kinetochore complex and chromosomal segregation during mitosis, was mechanically linked to altered metabolism and progression in prostate cancer. [Cell Cycle] Abstract

Knockdown of SRPX2 Inhibits the Proliferation, Migration, and Invasion of Prostate Cancer Cells through the PI3K/Akt/mTOR Signaling Pathway

Scientists investigated the expression and functional role of sushi repeat-containing protein X-linked 2 (SRPX2) in human prostate cancer. Knockdown of SRPX2 inhibited the proliferation, migration, and invasion of prostate cancer cells, as well as prevented the epithelial-mesenchymal transition process in prostate cancer cells. [J Biochem Mol Toxicol] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Post-GWAS in Prostate Cancer: From Genetic Association to Biological Contribution

The authors summarize the main molecular mechanisms of potential causal variants at prostate cancer risk loci and explore the major challenges in moving from association to functional studies and their implication in clinical translation. [Nat Rev Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

eFFECTOR Initiates Dosing in Phase II Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)

eFFECTOR Therapeutics, Inc. announced that it has dosed the first patient in a Phase II trial of tomivosertib in men with advanced CRPC who experienced progression on a secondary hormonal agent. Tomivosertib is a highly selective inhibitor of MNK 1 and MNK 2, kinases which promote tumor growth and immune evasion. [eFFECTOR Therapeutics, Inc.] Press Release

Constellation Pharmaceuticals Initiates Phase II Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Based on encouraging results from the Phase Ib portion of ProSTAR, the company has initiated dosing in the randomized Phase II portion studying CPI-1205 in combination with enzalutamide versus enzalutamide alone. Constellation has also decided to expand the Phase II portion of the study by adding an arm evaluating CPI-1205 in combination with abiraterone in the second-line setting. [Constellation Pharmaceuticals, Inc.] Press Release

The End of DACA Would Be a Blow to Science

With the end of Deferred Action for Childhood Arrivals (DACA), undocumented scientists will lose what few protections they currently have under immigrant law, lose their access to their scientific research, and once again live in fear, as they are caught in legal limbo. [Scientific America] Editorial

South Korean Scientists Protest Treatment of University President Accused of Misusing Funds

Researchers in South Korea have criticized the nation’s science ministry for its handling of an investigation into the president of the Korea Advanced Institute of Science and Technology (KAIST) in Daejon, the country’s top technical university. The science ministry alleges that KAIST leader Shin Sung-Chul made illegal payments to a California lab, but many scientists see a political purge. [Nature News] Editorial

NIH Report Scrutinizes Role of China in Theft of U.S. Scientific Research

Institutions across the U.S. may have fallen victim to a tiny fraction of foreign researchers who worked to feed American intellectual property to their home countries, an advisory committee to the National Institutes of Health (NIH) found in a report. [STAT News] Editorial

NEW 34^th Annual EAU Congress
March 15-19, 2019
Barcelona, Spain

Visit our events page to see a complete list of events in the community.

NEW Tenure-Track/Tenured Faculty Positions – Cancer Biology (University of Chicago)

Postdoctoral Associate – Prostate Cancer (Baylor College of Medicine)

Assistant Professor – Department of Integrative Biology & Pharmacology (University of Texas Health Science Center at Houston)

Faculty & Leadership Positions- Cancer-Focused Target & Drug Discovery (The University of New Mexico)

Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine)

Postdoctoral Fellow – Advanced Prostate Cancer Research (Cleveland Clinic)

Posdoctoral Position – Prostate Cancer Research (Louisiana State University Health Sciences Center)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.